1 / 5

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population. F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159. Characteristics of new users of statins, by persistence and average dose of statin use during the first 2 years of treatment.

makaio
Download Presentation

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

  2. Characteristics of new users of statins, by persistence and average dose of statin use during the first 2 years of treatment F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

  3. Effect of persistence and dose of statin use during the first 2 years of treatment on risk of hospitalization for myocardial infarction, by type of prevention F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

  4. Equipotency and percentage reduction in total cholesterol according to the different types and doses of statins F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

  5. Type, dose, and equipotency of the statin last prescribed before the start of outcome follow-up in 2-year persistent users, by average equipotent dose during the first 2 years of treatment F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

More Related